Dergiler / Organic Communications / 2021 / Cilt: 14 - Sayı: 1

Exploring the in-silico approach for assessing the potential of natural compounds as a SARS-CoV-2 main protease inhibitors

Sayfa
58–72
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

However, further research is necessary to investigate the ability of these compounds as COVID-19 inhibitors.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:The SARS-CoV-2 virus emerged as a major cause of the COVID-19 pandemic in December 2019.
📊
Temel Bulgular & Veri:Therefore, in the present study, a total of 12 active constituents from natural products like Ashwagandha, Tinospora cordifolia, Tea, Neem and lemon balm were docked, using the Autodock tool, onto the crystal structure of SARS CoV-2 main protease (PDB ID-5R80), to study their capability to act as main protease (Mpro) COVID-19 inhibitors.
💡
Sonuç & Katkı:However, further research is necessary to investigate the ability of these compounds as COVID-19 inhibitors.
🔬Tür:Araştırma Makalesi
📍Kapsam:2019 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

The SARS-CoV-2 virus emerged as a major cause of the COVID-19 pandemic in December 2019. Many attempts have been made to block the viral infection by targeting various processes like its entry, uncoating, replication, activating T cells response, and rising antibody titer. Also, many drugs are repurposed like remdesivir, dexamethasone, tocilizumab, hydroxychloroquine based on their established therapeutic efficacy against other viruses in the past. Natural products (NP) consist of a promising candidate and are needed to evaluate those molecules with molecular docking for preliminary screening and in vitro studies. Therefore, in the present study, a total of 12 active constituents from natural products like Ashwagandha, Tinospora cordifolia, Tea, Neem and lemon balm were docked, using the Autodock tool, onto the crystal structure of SARS CoV-2 main protease (PDB ID-5R80), to study their capability to act as main protease (Mpro) COVID-19 inhibitors. All NPs derivatives displayed good binding energies (ΔG) ranging from -8.8 to -5.2 kcal/mol, but berberine, epicatechin, and rosmarinic acid were found most potent, among others. Therefore, good binding energy, druglikeness, and efficient pharmacokinetics suggest the potential of NPs derivatives as SARS-CoV-2 main protease (Mpro) inhibitors. However, further research is necessary to investigate the ability of these compounds as COVID-19 inhibitors.

🔖

Bu Makaleye Atıf Yap

PATAL, A., PATEL, A., HEMANİ, R., SOLANKİ, R., KANSARA, J., PATEL, G., PRADHAN, S., BAMBHAROLİYA, T. (2021). Exploring the in-silico approach for assessing the potential of natural compounds as a SARS-CoV-2 main protease inhibitors. Organic Communications, Cilt: 14 - Sayı: 1, 58–72. https://ajindex.com/articles/288446

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (9)

  1. Kahn, J.; McIntosh, K. History and recent advances in coronavirus discovery. Pediatr. Infect. Dis J. 2005, 24, S223-S227
  2. Gorbalenya, A.; Baker, S.; Baric, R.; de Groot, R.; Drosten, C.; Gulyaeva, A.; Haagmans, B.; Lauber, C.; Leontovich, A.; Neuman, B.; Penzar, D.; Perlman, S.; Poon, L.; Samborskiy, D.; Sidorov, I.; Sola, I.; Ziebuhr, J. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-Ncov and naming it SARS-Cov-2. Nat. Microbiol. 2020, 5, 536-544
  3. Jiang, S.; Shi, Z.; Shu, Y.; Song, J.; Gao, G.; Tan, W.; Guo, D. A Distinct name is needed for the new coronavirus. Lancet. 2020, 395, 949-950. [4] https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200316-sitrep-56-covid-19.pdf (accessed Aug 20, 2020)
  4. Li, Q.; Guan, X.; Wu, P.; Wang, X.; Zhou, L.; Tong, Y.; Ren, R.; Leung, K.; Lau, E.; Wong, J.; Xing, X.; Xiang, N.; Wu, Y.; Li, C.; Chen, Q.; Li, D.; Liu, T.; Zhao, J.; Liu, M.; Tu, W.; Chen, C.; Jin, L.; Yang, R.; Wang, Q.; Zhou, S.; Wang, R.; Liu, H.; Luo, Y.; Liu, Y.; Shao, G.; Li, H.; Tao, Z.; Yang, Y.; Deng, Z.; Liu, B.; Ma, Z.; Zhang, Y.; Shi, G.; Lam, T.; Wu, J.; Gao, G.; Cowling, B.; Yang, B.; Leung, G.; Feng, Z. Early transmission dynamics in wuhan, china, of novel coronavirus–infected pneumonia. New Engl. J. Med. 2020, 382, 1199-1207
  5. Chen, W.; Vermaak, I.; Viljoen, A. Camphor—A fumigant during the black death and a coveted fragrant wood in ancient egypt and babylon—A review. Molecules, 2013, 18, 5434-5454
  6. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; Cheng, Z.; Yu, T.; Xia, J.; Wei, Y.; Wu, W.; Xie, X.; Yin, W.; Li, H.; Liu, M.; Xiao, Y.; Gao, H.; Guo, L.; Xie, J.; Wang, G.; Jiang, R.; Gao, Z.; Jin, Q.; Wang, J.; Cao, B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020, 395, 497-506
  7. Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; Qiu, Y.; Wang, J.; Liu, Y.; Wei, Y.; Xia, J.; Yu, T.; Zhang, X.; Zhang, L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020, 395, 507-513
  8. Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J.; Wang, B.; Xiang, H.; Cheng, Z.; Xiong, Y.; Zhao, Y.; Li, Y.; Wang, X.; Peng, Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus– infected pneumonia in Wuhan, China. JAMA- J. Am. Med. Assoc. 2020, 323, 1061
  9. Phela